Skip to main content
Clinical Trials/NCT05584540
NCT05584540
Withdrawn
Not Applicable

The UNTIRE App Trial: The Feasibility of Using the Untire App for the Colorectal Cancer Patient to Manage Their Cancer Related Fatigue

Dana-Farber Cancer Institute1 site in 1 country60 target enrollmentJanuary 30, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Dana-Farber Cancer Institute
Enrollment
60
Locations
1
Primary Endpoint
Enrollment Rate
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

This research is being done to find out if using a smartphone app as digital treatment to reduce Cancer Related Fatigue is feasible and easy to use.

This research study is evaluating a smartphone application named the "Untire" app. The Untire app was designed as a digital treatment plan for people experiencing Cancer Related Fatigue (CRF).

Detailed Description

This is a single arm, pilot study evaluating the feasibility, acceptability, and effectiveness of a self-managed digital therapeutic application, the Untire App, for the treatment of cancer-related fatigue in the Colorectal (CRC) cancer patient community. The Untire app was developed by Psychology Oncologists and combines proven treatments for Cancer Related Fatigue like cognitive behavioral therapy, mindfulness exercises, physical activities, education, and positive tips. The Untire app helps a patient recognize and learn about daily behaviors, fatigue levels, and energy levels. The Untire app has been tested on all different cancer types globally and has been proven to decrease fatigue and improve overall quality of life but this is the first-time investigators are examining the strengths and weaknesses of using the Untire app as a digital treatment plan for Cancer Related Fatigue. The research study procedures include screening for eligibility and study interventions including smartphone app use and evaluations with questionnaires and follow up visits. Participants will be in this research study for up to 12 months. It is expected that about 60 people will take part in this research study.

Registry
clinicaltrials.gov
Start Date
January 30, 2025
End Date
January 30, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nina Grenon, NP

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • \>/= 18 years of age
  • Owns a smart phone or Ipad
  • Diagnosis of Metastatic Colorectal Cancer, adenocarcinoma
  • Actively undergoing treatment for Metastatic disease
  • Speak and read English at a 6th grade level or higher
  • A score of 1 or greater on the PRO CTACE DFCI fatigue (questions 53a or 53b)

Exclusion Criteria

  • Patients in Surveillance
  • Patients receiving end of life care
  • Patients taking dexamethasone other than for the control of nausea
  • Patients taking methylphenidate (Ritalin) for the treatment of CRF

Outcomes

Primary Outcomes

Enrollment Rate

Time Frame: 3 months

Primary outcome is feasibility. Feasibility will be described as the number and percentage of enrolled patients that used the app more than once.

Secondary Outcomes

  • CSQ-I Score(3 months)

Study Sites (1)

Loading locations...

Similar Trials